Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
  • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/74—Synthetic polymeric materials
  • A61K31/765—Polymers containing oxygen
  • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
  • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Definitions

• the present invention relates to a lubricious composition for use in particular in human vaginal delivery.
• the vaginal delivery of a child is a complex process and is determined by three key factors: the birth object (fetus, amnion, placenta), the birth canal (consisting of a bony portion and a soft tissue tube) and the birthing force.
• birth object fetus, amnion, placenta
• birth canal consisting of a bony portion and a soft tissue tube
• birthing force various birth forces are known, which promote or inhibit the vaginal birth (vaginal bearing) of a human fetus.
• birth-promoting forces here are labor and gravity
• birth-inhibiting forces are the elasticity of the cervix and the birth canal.
• the birth of a human child is divided into 3 phases: the opening period, the expulsion period and the placental period.
• the average length of birth for first-time mothers is 12 hours, for multipeny women it is 8 hours on average.
• the shorter average duration of labor in multipregnant women compared to first-time mothers is due to the reduced elastic force of the birth canal, as in multi-pregnancies the soft tissue tube (inner uterine segment - cervical canal - soft tissue insertion tube (vagina and vulva)) are rolled out by the previous vaginal births on human birth mechanics, therefore, is that the force of extension of the birth canal (the force necessary to open, stretch and roll out the birth canal) is considered to be an essential force impeding the birth (Dudenhausen, Schneider, gynecology and obstetrics, De Gruyter (1994), pages 113 to 121).
• a key difference between birth in the animal and human birth is that the role of the amniotic fluid in human delivery at the appointment has no significant relevance to the lubrication of the birth canal, but can increase the resulting frictional forces.
• Amniotic fluid as an aqueous substance in humans, does not have a pronounced lubricating effect per se.
• the Vernix Caseosa as the only lubricating substance of the birth object, is usually no longer available at the date of birth and is in any case only slightly effective on the head.
• the use of amniotic fluid or amniotic fluid replacement for lubrication of the birth canal before or during a vaginal delivery in humans is therefore an insufficiently suitable measure for reducing the frictional forces and for facilitating the vaginal delivery in humans.
• US Pat. No. 3,814,797 discloses aqueous slip compositions based on (A) potassium metaphosphate, (B) alginic acid, carboxymethyl cellulose, carboxymethyl starch and salts thereof and (C) the sodium salt of a weak acid, for example sodium carbonate or sodium phosphates.
• U.S. Patent 3,971,848 discloses a mucous membrane lubricant composition containing a mixture of fucoidin and an alginate.
• the composition may optionally be mixed with carboxymethyl cellulose, sodium polyacrylate, potassium sodium polyphosphate, polyethylene oxide or the like and used for the purpose of birthing relief.
• US Pat. No. 4,267,168 discloses a liquid biocidal composition which can be used as a detergent, as a surface disinfectant or as a vaginal lubricant.
• the composition contains lauryldiethanolamide, propylene glycol, glycerin, sodium polypetate and silver ions. It has a pH in the range of 7.2-7.8.
• JP 46024256 discloses a lubricant composition consisting essentially of polyacrylate which can be used as a supporting uterine fluid in veterinary medicine.
• JP 45000153 and JP 4500012 disclose a birth control veterinary lubricant composition containing a salt or an ester of alginic acid and gum arabic.
• JP 46034991 discloses a lubricant composition containing polyethylene oxide powder in a liquid consisting of an organic solvent in a concentration of> 80%, hydroxypropyl cellulose, sodium sulfate and a detergent.
• the composition may be used after dilution to facilitate the extraction of a fetus in veterinary medicine.
• PCT / EP03 / 00548 discloses the use of a physiologically acceptable organic substance for the preparation of a composition containing no alkali metal salts of metaphosphates - A - for use as a lubricant in vaginal births of women. Numerous examples of suitable, physiologically harmless organic substances are mentioned.
• the object of this invention is the reduction of the newly recognized essential obstetric force, namely the frictional force between birth object and birth canal, by the use of a lubricant in humans.
• the object underlying the present invention was to provide a composition for facilitating human birth, which is physiologically compatible and has both good adhesion properties and lubricity.
• a bioadhesive composition having a lubricating action comprising (a) a polyacrylic acid, (b) a water-soluble thickener and (c) a humectant and (d) optionally water.
• Component (a) of the composition according to the invention is a polyacrylic acid which may be crosslinked or / and chemically modified or a salt of such a polyacrylic acid or a mixture of several polyacrylic acids.
• the average molecular weight of the acrylic acid polymers is chosen to have bioadhesive properties in the intended application. Usually, the molecular weight is in the range of at least 2,000 D and preferably up to 500,000 D. 5
• Preferred polyacrylic acids are crosslinked acrylic acid polymers, for example acrylic acid homopolymers, copolymers or interpolymers or salts of such polymers, for example alkali metal or alkaline earth metal salts.
• acrylic acid homopolymers for example acrylic acid homopolymers, copolymers or interpolymers or salts of such polymers, for example alkali metal or alkaline earth metal salts.
• carbomer homopolymers ie, high molecular weight polymers o of acrylic acid which are crosslinked with Polyalkenylethem of sugars or polyalcohols, such as allyl sucrose, allyl pentaerythritol, etc., such as Carbopol ® 940 NF, 974P NF or 980 NF.
• carbomer copolymers ie high molecular weight copolymers of acrylic acid and crosslinked with Polyalkenylethem of sugars or polyalcohols, such as Carbopol ® 1382, Carbopol ® 1342 NF, Carbopol ® ETD 2020, Pemulen TR1 ® NF and Pemulen ® TR2 NF.
• Carbomer interpolymers ie carbomer homopolymers or copolymers that contain a heterologous polymer such as a block copolymer of polyethylene glycol and a long chain, for example, DC 2 4-alkyl acid, such as Carbopol ® Ultrez 10, 20 or 21, or Carbopol ® Ultrez 10 NF.
• polycarbophils ie polyacrylic acids which are cross-linked with divinyl glycol, such as Noveon ® AA-1 USP, or Calciumpolycarbophile, ie calcium salts of polyacrylic acid crosslinked with divinyl glycol, such as Noveon ® CA-1 USP and CA-2 USP.
• the polyacrylic acid homopolymers usually have a content of COOH groups of 56-68%, while the polyacrylic acid copolymers have a content of 52-62% of COOH groups.
• the proportion by weight of component (a) in the total weight of the composition can be varied widely, for example from 0.1-15%.
• the proportion by weight of component (a) is preferably 0.1-10%, more preferably 0.2-1% and even more preferably 0.4-0.7%. Most preferred is the weight fraction of 0.45-0.5%.
• Component (b) of the composition is a water-soluble thickener or a mixture of several thickeners.
• Preferred examples are cellulose derivatives, in particular hydrophilic modified cellulose derivatives, such as hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, or / and hydroxypropylmethylcellulose.
• Further preferred water-soluble thickeners are mucopolysaccharides, in particular hyaluronic acid.
• the component (b) is usually in a weight proportion of 0.1-30%, preferably 1-10%, more preferably 2.5-7.5% and most preferably 4-6% based on the total weight of Composition available.
• Component (c) of the composition is a humectant or a mixture of several humectants.
• Preferred examples are pharmaceutically acceptable polyalcohols, such as propylene glycol, in particular 1,2-propylene glycol, glycerol or / and polyethylene glycol, in particular liquid polyethylene glycol.
• Component (c) is usually present in a weight proportion of 0.1-30%, preferably 10-30%, more preferably 15-25% and most preferably 18-22% based on the total weight of the composition.
• the optional component (d) of the composition is water.
• the water is usually present in a weight proportion of 40-95%, preferably 60-85%, more preferably 70-80% and most preferably 72-77% based on the total weight of the composition.
• the composition may also be made with a lower water content or dry, e.g. as a powder, present and / or diluted and diluted shortly before use.
• the composition may contain auxiliaries, such as, for example, surfactants, dispersants, further thickeners, reagents for adjusting a pH, carriers, fillers, stabilizers or / and preservatives.
• auxiliaries such as, for example, surfactants, dispersants, further thickeners, reagents for adjusting a pH, carriers, fillers, stabilizers or / and preservatives.
• the composition is free of preservatives.
• the composition is free from alginic acid or alginates, since the addition of these substances often leads to the formation of undesired discolorations or precipitations.
• the composition is preferably free from Metaphosphates and / or heavy metal ions, in particular silver ions.
• the composition further contains
• Ethylenediaminetetraacetic acid or / and pharmaceutically acceptable salts thereof.
• the composition contains means for adjusting a substantially isotonic osmolarity, for example, salts such as sodium chloride in a weight proportion usually from 0.1-5%, preferably from 0.3-0.6%, more preferably from 0.45-0 , 55%, and most preferably about 0.49-0.50%, based on the total weight of the composition.
• a substantially isotonic osmolarity for example, salts such as sodium chloride in a weight proportion usually from 0.1-5%, preferably from 0.3-0.6%, more preferably from 0.45-0 , 55%, and most preferably about 0.49-0.50%, based on the total weight of the composition.
• the composition of the present invention is preferably a gel which desirably has a substantially colorless and transparent appearance.
• the composition may also be in the form of solid dosage forms, such as tablets, powders, pastes, ovules, dragees, effervescent tablets or suspensions thereof, or in the form of a foam.
• the pH of the composition is preferably adjusted to a range of 4-7, more preferably of 5-6 and most preferably of 5.5-6 by the addition of suitable reagents, eg acids such as HCl or bases such as NaOH.
• suitable reagents eg acids such as HCl or bases such as NaOH.
• the determination of the pH is preferably carried out potentiometrically on a 1: 9 diluted gel in a 1, 0% strength KNO 3 solution.
• the viscosity of the composition is preferably in the range of 1-40 Pa.s, more preferably in the range of 10-18 Pa.s.
• the determination of the viscosity is carried out preferably with a rotational viscometer, speed series N, level 4, sensor SV DIN, time 60 s, 20 revolutions at 20 0 C.
• the determination of the viscosity with a Brookfield RVT viscometer at a rotational speed of the spindle of 0 , 05 to 100 revolutions per minute.
• the conductivity of the composition is preferably in the range of - 8th -
• the composition desirably has thixotropic and / or pseudoplastic properties, the viscosity decreasing under the influence of increasing shear stress and / or shear rate. Furthermore, the composition preferably has a high initial shear stress and / or a pseudoplastic behavior, i. the adhesiveness of the composition decreases under the influence of increasing shear stress.
• the composition may be in sterile form, e.g. steam sterilization and / or sterilization by irradiation, e.g. by gamma irradiation, is possible.
• the composition may also be used in non-sterilized form and / or contain preservatives and / or biocidal substances.
• the preparation of the composition preferably comprises the following steps:
• composition galenic form may depend on the intended for the composition galenic form or possibly existing additives are varied.
• water and / or humectants may be at least partially removed during the process and / or added.
• the composition is in packaged dosage units in a volume of 5-500 ml, more preferably in packaged dosage units in a volume of 10-20 ml.
• the composition is advantageously in a package, for example cans, syringes, e.g. Disposable syringes, or tubes, or it can be applied as a vaginal vein.
• a vaginal applicator can be used.
• the composition can be applied to the surface of the birth canal with fingers or spatulas. More useful are tubes or syringes from which the composition can be applied by pressure on the surface of the birth canal.
• the size of the package can be chosen so that the amount of composition for a single application is sufficient.
• the tubes or syringes may be provided with an extension which corresponds substantially to the length of the birth canal, at the end of which the outlet for the composition is attached.
• the outlet opening is expediently designed, e.g. as a circular slit opening, the composition can be distributed completely and substantially evenly on the surface of the birth canal.
• composition to be used according to the invention is simple and effective if the composition is applied before the onset of regular labor, in the opening phase or / and in the expulsion phase.
• the application can be done one or more times.
• An application just before or during the opening phase can have the advantage of softening the tissue in the birth canal, which also facilitates childbirth.
• the composition can also be used to facilitate the placenta solution.
• the composition may additionally contain one or more pharmaceutically active substances which serve as medicaments for certain birth indications, for example birth control or birth promotion agents, pain relief agents and / or infection prevention agents.
• the amount of pharmaceutical active ingredients may be, for example, 0.0001-50% by weight, preferably 0.01-10% by weight and particularly preferably 0.01-5% by weight, based on the total weight of the composition.
• birth initiating agents are oxytocin, dinoprostone, sulprostone, misoprostol and hyaluronidase.
• birth-inhibiting substances are chondroitin sulfate, hexoprenaline, fenoterol, magnesium sulfate, atosiban, calcium antagonists and nitroglycerin.
• painkillers include bupivacaine, carbostesin, lidocaine, mepivacaine, rapidocaine, scandicaine, solarcain and xylesin.
• anti-infective or biocidal substances are antibacterial and / or antimicrobial and / or antiviral substances, such as quaternary ammonium compounds, chlorhexidine, povidone-iodine and iodine, and iodine-containing compounds.
• antiviral substances e.g. against the transmission of herpes or HIV from the mother to the child
• antiviral substances e.g. against the transmission of herpes or HIV from the mother to the child
• nucleoside analogues e.g. Nucleoside analogues, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors.
• pulmonary surfactants pulmonary surfactants
• pulmonary surfactants pulmonary surfactants
• the composition is particularly suitable as a lubricant to facilitate vaginal human birth and / or to facilitate placental solution. It may be applied one or more times as needed before or / and after the onset of regular labor activity. The application is preferably in the birth canal including the cervix. Intra-amnial administration may also be appropriate.
• human birth can be greatly facilitated and even shortened in time, especially in first-time mothers, by covering the walls of the cervix or / and vagina (birth canal) with the lubricant before or / and during gestation.
• the friction between birth canal and birth object can be greatly reduced both in the opening period and in the expulsion period.
• the risk of injury such as soft tissue extension tubulation, pelvic floor damage, vaginal tears, perineal injuries, rectal injuries, uterine ruptures, blood loss
• long-term damage e.g. Urinary incontinence, faecal incontinence, sexual dysfunction and mental disorders, restricted or prevented.
• the labor of labor can be reduced, which can lead to a prevention or reduction of vaginal surgery or caesarean sections.
• a manual placenta solution can also be facilitated by the lubricant according to the invention.
• the birth gel is unpacked while maintaining sterile conditions.
• the gel is then one or more intermittently on the birth canal applied by hand or other means until the development of the child's head.
• the goal here is to cover the birth canal with the lubrication gel as completely as possible.
• the gel on the child's face can be wiped off with a cloth and if necessary the mouth and nose region can be additionally sucked off.
• the full development of the child is ideally done with the help of a cloth, so that the child does not slide out of the hands.
• the birth canal is rinsed with an aqueous aseptic solution, preferably with a mild aqueous aseptic saline solution, to dissolve the lubricant. This may occur during or independently of the treatment of injuries to the perineum or the birth canal.
• the lubricating gel may additionally be used to facilitate the delivery of the placenta or the manual solution of the placenta. In the birth management of a pelvic end position is proceeded analog and adapted.
• Carbopol ® 940 4.85 mg / g
• Hydroxyethylcellulose (Natrosol 250 G): 45.00 mg / g
• Hydroxyethylcellulose (Natrosol 250 G): 45.00 mg / g
• Hydroxyethyl cellulose (Natrosol 250 M): 2.5% (m / m)
• Carbopol 980 NF 0.485% (m / m)
• Hydroxyethylcellulose (Natrosol 250 G): 45.00 mg / g
• Hydroxyethylcellulose (Natrosol 250 G): 45.00 mg / g
• Hydroxyethyl cellulose (Natrosol 250 M): 2.5% (m / m) Noveon AA-1 USP Polycarbophil: 4.85 mg / g
• the pH is determined potentiometrically using a suitable pH meter. For measurement, a 10% solution of the gel is added in a 1.0% strength KNO 3 solution.
• Viscosity determination The viscosity is determined with a rotational viscometer (instrument and measuring parameters: speed series N / stage 4 / sensor SV DIN / time 60s / 20 revolutions / min). All measurements are carried out at 20 ° C.
• Density The density is determined by means of a pycnometer or by another, equally suitable instrument. The calculation is done according to the formula
• ⁇ c 20 m ⁇ 0.99703 + 0.0012 (g / cm 3) ⁇
• Conductivity The conductivity is determined by means of a conductivity meter in accordance with DIN 61326A1 / VDE 0843 Part 20 / A1.
• the finished gel is slightly opaque and transparent and odorless, has a pH of 5.5 to 6.0.
• the viscosity is 16000 mPas (measured with a Haake viscometer, model VT 500, speed series N, stage 4, sensor SV DIN, time 60 s, 20 revolutions / min, at 20 ° C).
• the gel is transferred to a sterile filling line and 1000 syringes are filled with 10 g of gel.
• the exit of the syringe is capped, then sealed in a foil and then sterilized at 121 ° C for 15 minutes to ready-to-use product.
• a lubricant was used according to the invention. Not only was the lubrication gel used for vaginal examination as usual, but the birth canal was intermittently covered with the lubricant manually. The amount of lubricant required for this was 10 to 15 times higher than when used for vaginal examination. In this group, it was found that the average duration of birth was significantly shorter than the established norm values and that the women gave birth more easily vaginally than comparable first-time mothers without the use of a lubricant. Overall, the birth trauma was smaller for mother and child. Furthermore, no vaginal operative termination of labor had to be performed in this panel and no birth canal injuries such as vaginal tears were detected.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Reproductive Health (AREA)
• Engineering & Computer Science (AREA)
• Inorganic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Urology & Nephrology (AREA)
• Gynecology & Obstetrics (AREA)
• Molecular Biology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Dermatology (AREA)
• Endocrinology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=35613872

Family Applications (1)

Country Status (18)

Cited By (1)

Families Citing this family (20)

Family Cites Families (41)

• 2004
  • 2004-11-11 DE DE102004054552A patent/DE102004054552A1/de not_active Ceased
• 2005
  • 2005-11-09 TW TW094139313A patent/TW200631603A/zh unknown
  • 2005-11-09 AR ARP050104695A patent/AR052030A1/es not_active Application Discontinuation
  • 2005-11-10 MX MX2007005587A patent/MX2007005587A/es active IP Right Grant
  • 2005-11-10 US US11/718,995 patent/US8703171B2/en not_active Expired - Fee Related
  • 2005-11-10 EA EA200701029A patent/EA012391B1/ru not_active IP Right Cessation
  • 2005-11-10 UA UAA200706411A patent/UA91526C2/uk unknown
  • 2005-11-10 JP JP2007540579A patent/JP5641677B2/ja not_active Expired - Fee Related
  • 2005-11-10 MY MYPI20055275A patent/MY144274A/en unknown
  • 2005-11-10 CN CNA2005800444923A patent/CN101087587A/zh active Pending
  • 2005-11-10 AU AU2005303970A patent/AU2005303970B2/en not_active Ceased
  • 2005-11-10 WO PCT/EP2005/012058 patent/WO2006050951A1/de active Application Filing
  • 2005-11-10 CA CA2585976A patent/CA2585976C/en not_active Expired - Fee Related
  • 2005-11-10 EP EP05802296A patent/EP1809239A1/de not_active Withdrawn
  • 2005-11-10 KR KR1020077012725A patent/KR20070090181A/ko not_active Application Discontinuation
  • 2005-11-10 BR BRPI0517799-5A patent/BRPI0517799A/pt not_active IP Right Cessation
• 2007
  • 2007-05-03 IL IL182977A patent/IL182977A/en active IP Right Grant
  • 2007-05-10 ZA ZA200703777A patent/ZA200703777B/en unknown
• 2013
  • 2013-02-26 JP JP2013035709A patent/JP2013100364A/ja active Pending
• 2014
  • 2014-03-04 US US14/196,157 patent/US20140187650A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events